AIM:The heptadecapeptide nociceptin alias orphanin FQ is the endogenous agonist of opioid receptor-likel receptor. It is involved in modulation of pain and cognition.High blood level was reported in patients with acut...AIM:The heptadecapeptide nociceptin alias orphanin FQ is the endogenous agonist of opioid receptor-likel receptor. It is involved in modulation of pain and cognition.High blood level was reported in patients with acute and chronic pain, and in Wilson disease.An accidental observation led us to investigate nociceptin in hepatocellular carcinoma. METHODS:Plasma nociceptin level was measured by radioimmunoassay,aprotinin was used as protease inhibitor. Hepatocellular carcinoma was diagnosed by laboratory, ultrasound,other imaging,and confirmed by fine needle biopsy.Results were compared to healthy controls and patients with other chronic liver diseases. RESULTS:Although nociceptin levels were elevated in patients with Wilson disease (14.0±2.7 pg/mL,n=26), primary biliary cirrhosis (12.1±3.2 pg/mL,n=21) and liver cirrhosis (12.8±4.0 pg/mL,n=15) compared to the healthy controls (9.2±1.8 pg/mL,n=29, P<0.001 for each),in patients with hepatocellular carcinoma a ten-fold increase was found (105.9±14.4 pg/mL,n=29,P<0.0001).High plasma levels were found in each hepatocellular carcinoma patient including those with normal alpha fetoprotein and those with pain (104.9±14.9 pg/mL,n=12) and without (107.7±14.5 pg/mL,n=6). CONCLUSION:A very high nociceptin plasma level seems to be an indicator for hepatocellular carcinoma.Further research is needed to clarify the mechanism and clinical significance of this novel finding.展开更多
Since 1994 we have treated 24 cases of primary hepatocarcinoma with a novel preparation Gan Fu Le (肝复乐). The effect was definite as reported in the following.Subjects and methodA total of 24 cases of primary hepato...Since 1994 we have treated 24 cases of primary hepatocarcinoma with a novel preparation Gan Fu Le (肝复乐). The effect was definite as reported in the following.Subjects and methodA total of 24 cases of primary hepatocarcinoma (21 males and 3 females) aged 42-73 (mean 57) years old were enrolled in the treatment group and treated only with Gan Fu Le, 10 tablets, t.i.d. for 2 months as one therapeutic course.展开更多
文摘AIM:The heptadecapeptide nociceptin alias orphanin FQ is the endogenous agonist of opioid receptor-likel receptor. It is involved in modulation of pain and cognition.High blood level was reported in patients with acute and chronic pain, and in Wilson disease.An accidental observation led us to investigate nociceptin in hepatocellular carcinoma. METHODS:Plasma nociceptin level was measured by radioimmunoassay,aprotinin was used as protease inhibitor. Hepatocellular carcinoma was diagnosed by laboratory, ultrasound,other imaging,and confirmed by fine needle biopsy.Results were compared to healthy controls and patients with other chronic liver diseases. RESULTS:Although nociceptin levels were elevated in patients with Wilson disease (14.0±2.7 pg/mL,n=26), primary biliary cirrhosis (12.1±3.2 pg/mL,n=21) and liver cirrhosis (12.8±4.0 pg/mL,n=15) compared to the healthy controls (9.2±1.8 pg/mL,n=29, P<0.001 for each),in patients with hepatocellular carcinoma a ten-fold increase was found (105.9±14.4 pg/mL,n=29,P<0.0001).High plasma levels were found in each hepatocellular carcinoma patient including those with normal alpha fetoprotein and those with pain (104.9±14.9 pg/mL,n=12) and without (107.7±14.5 pg/mL,n=6). CONCLUSION:A very high nociceptin plasma level seems to be an indicator for hepatocellular carcinoma.Further research is needed to clarify the mechanism and clinical significance of this novel finding.
文摘Since 1994 we have treated 24 cases of primary hepatocarcinoma with a novel preparation Gan Fu Le (肝复乐). The effect was definite as reported in the following.Subjects and methodA total of 24 cases of primary hepatocarcinoma (21 males and 3 females) aged 42-73 (mean 57) years old were enrolled in the treatment group and treated only with Gan Fu Le, 10 tablets, t.i.d. for 2 months as one therapeutic course.
